Global Anti-Migraine Drugs Market: Trends and Opportunities (2014-19) – Daedal Research

The report titled “Global Anti-Migraine Drugs Market: Trends and Opportunities (2014-2019)” provides an insight into migraine drugs with a special focus on Triptans.
Spread the Word
Listed Under

Anti Migraine Drugs Market


Delhi - Delhi - India


DELHI, India - June 18, 2014 - PRLog -- The report also includes the market value, segmentation, types of diagnosis and treatment for migraine. It also discusses key growth drivers and upcoming trends of the market. Further, key manufacturers of anti-migraine drugs like Endo International Inc, Imapc Laboratories, GlaxoSmithKline and Pfizer Inc. are profiled in the report.

Segments Coverage

Q Triptans
Q Ergot Alkaloids

Company Coverage

Q Endo International Inc.
Q IMPAX Laboratories Inc.
Q GlaxoSmith Kline (GSK)
Q Pfizer Inc.

Executive Summary

Migraine, a condition of recurring headaches and is accompanied by symptoms like nausea, vomiting, dizziness and sensitivity to light and noise ranks among the World’s Top 20 disabling medical illnesses. It is anticipated that launches of many generic migraine drugs over the next several years will steadily increase diagnosis and drug-treatment rates, leading to sustained annual global growth of anti-migraine drugs market. Other factors contributing to the growth of these drugs include awareness among the people about proper diagnosis and treatment of migraine, rise in medical expenditures and new drugs launches.

Acute migraine treatment market is dominant by Triptans and most of them are available as pills. Triptans like Sumatriptan and Zolmitriptan are also available as nasal sprays whereas rizatriptan and zolmitriptan are available as tablets that dissolve in mouth. In next 5-10 years, cost of migraine drugs is anticipated to decline due to many generic entrants as most of them are losing their patents. Growing awareness of migraine in the emerging countries and fall in prices will facilitate the growth of anti-migraine drugs market. In addition, with the development of new treatment therapies like calcitonin gene-related peptides (CGRP) receptor antagonist and BOTOX the demand for anti-migraine drugs is anticipated to grow further.

The US is the largest market for anti-migraine drugs and there are number of companies that manufacture these drugs. Major companies include Impax, Endo Pharmaceuticals, Pfizer, GlaxoSmith Kline, Nautilus and Allergan.

Table of Contents:

1. Executive Summary

2. Migraine

2.1 An Overview

2.2 Different Types of Migraines

2.2.1 Migraine without Aura

2.2.2 Migraine with Aura

2.2.3 Other Types of Migraine

2.3 Diagnosis and Treatment

3. Anti-Migraine Drugs Market

3.1 Global Anti-Migraine Drugs Market Size (2009-2013)

3.2 Forecast- Global Anti-Migraine Drugs Market Size (2014-2019)

3.3 Segmentation by Type of Drugs Used

3.4 Migraine Specific Drugs

3.4.1 Triptan

Types of Triptans

Effectiveness of Triptans

Triptan Costs

3.4.2 Tezampanel

3.4.3 Ergots Alkaloids

3.5 Prevalence of Migraine

4. The US Migraine Market

4.1 Migraine Sufferers

4.2 Market Size

4.3 Triptans Sales

5. Migraine Market: Drivers & Challenges

5.1 Rising Healthcare Expenditures

5.2 Growth of Middle-Aged Population

5.3 Patent Expires of Migraine Drugs

6. Migraine Market: Key Challenges

6.1 Strict Regulations

6.2 Expensive Drugs

7. Migraine Market: Upcoming Trends

7.1 Calcitonin Gene-Related Peptides (CGRP) Antibodies

7.2 BOTOX for Migraine

7.3 Anti-Migraine Headbands & Devices

7.4 New Products Development

8. Migraine Market: Competitive Landscape

9. Migraine Market: Company Profiles

9.1 Endo International Plc.

9.1.1 Business Description

9.1.2 Financial Overview

9.1.3 Business Strategies

9.2 IMPAX Laboratories Inc.

9.2.1 Business Description

9.2.2 Financial Overview

9.2.3 Business Strategies

9.3 GlaxoSmithKline (GSK)

9.3.1 Business Description

9.3.2 Financial Overview

9.3.3 Business Strategies

9.4 Pfizer Inc.

9.4.1 Business Description

9.4.2 Financial Overview

9.4.3 Business Strategies

10.  About Us

List of Figures:

Figure 1: Pathways of Migraine

Figure 2: Global Migraine Drugs Market Size (US$ Billion), 2009-2013

Figure 3: Forecast of Global Migraine Drugs Market (US$ Billion), 2014-2019

Figure 4: Segmentation of Migraine Drugs by Types, 2013

Figure 5: Prevalence of Migraine Worldwide (2007-2013)

Figure 6: Total Number of Migraine Sufferers in the US in Million, 2012E-2017E

Figure 7: The US Migraine Drugs Market Size (US$ Billion), 2009

Figure 8: Share of the US in Overall Migraine Drugs Market, 2013

Figure 9: Market Shares of Triptan by Brands, 2013

Figure 10: Global Healthcare Expenditures Per Capita in US$, 2007-2013

Figure 11: World Population Ages Between 15-34 Years in Billion, 2007-2013

Figure 12: Global BOTOX Migraine Sales in US$ Million, 2012-2017

Figure 13: BOTOX Migraine Sales by Geography in US$ Million, 2012-2017

Figure 14: Migraine Drugs Share in Total Prescriptions, Nov 2012 vs Nov 2013

Figure 15: Migraine Drugs Share in Total Prescriptions (Excl acetaminophen products) by Players, Nov 2012 vs Nov 2013

Figure 16: Endo International Plc.- Revenue Segmentation by Business Segments, 2013

Table 10: Revenue Breakdown of Endo Pharmaceuticals Segment, 2013

Figure 17: Endo International Plc - Revenues from “Frova” (US$ Million) 2010-2013

Figure 18: Impax Laboratories – Revenue Segmentation by Business Segments, 2013

Figure 19: Revenue from Impax Division Segment, 2010-2013 (US$ Million)

Figure 20: GSK Revenue Segmentation by Business Areas, 2013

Figure 21: GSK- Revenues from Imigran/Imitrex Migraine Drugs Brands (US$ Million) 2011-2013

Figure 22: GSK- Distribution of Imigran/Imitrex Migraine Drugs by Geographic Areas, 2013

Figure 23: Pfizer’s Revenue Share by Business Segments (2013)

Figure 24: Pfizer – Revenues from Relpax Migraine Drug (US$ Million), 2011-2013

Table 1: Other Types of Migraines

Table 2: Types of Triptans Currently Available

Table 3: Effectiveness of Oral Triptans

Table 4: Frequency of Oral Triptan Side Effects

Table 5: Triptan Costs

Table 6: Tezampanel Drug Market, 2013

Table 7: Estimated Sales of Selected Migraine Drugs in the US, 2013

Table 8: Generic Availability of Select Migraine Products

Table 9: New Products for the Treatment and Prevention of Migraine

For further details, kindly visit :

Rajeev Kumar

(Business Development Manager)

Address:  36 SFS Flats

Paschim Vihar

New Delhi-110063

Mobile: +91-8743975789

Tel: +91-120-4553017

Mail ID -

Daedal Research
Email:*** Email Verified
Tags:Anti-migraine, Anti Migraine Drugs Market
Location:Delhi - Delhi - India
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share